Content about Hart-Scott-Rodino Antitrust Improvements Act

February 3, 2012
Regulatory waiting period for Bristol's Inhibitex acquisition expires

The regulatory waiting period standing between Bristol-Myers Squibb and its acquisition of drug maker Inhibitex has expired, giving Bristol the green light to buy the company.

NEW YORK — The regulatory waiting period standing between Bristol-Myers Squibb and its acquisition of drug maker Inhibitex has expired, giving Bristol the green light to buy the company.

Bristol said Friday that the expiration of the waiting period, mandated by the Hart-Scott-Rodino Antitrust Improvement Act of 1976, would allow it to acquire Inhibitex for $26 per share.

September 6, 2011
FTC requests additional information on ESI-Medco merger

The proposed merger between pharmacy benefit managers Express Scripts and Medco Health Solutions hit a speed bump Friday as the Federal Trade Commission requested additional information, indicating that the agency has raised antitrust concerns.

NEW YORK — The proposed merger between pharmacy benefit managers Express Scripts and Medco Health Solutions hit a speed bump Friday as the Federal Trade Commission requested additional information, indicating that the deal has raised antitrust concerns among regulators.

June 14, 2011
FTC issues 'second request' to Teva, Cephalon over deal

Before they can move ahead with their deal, drug makers Teva and Cephalon must provide the Federal Trade Commission with additional information related to Teva's pending acquisition of Cephalon.

JERUSALEM and FRAZER, Pa. — Before they can move ahead with their deal, drug makers Teva and Cephalon must provide the Federal Trade Commission with additional information related to Teva's pending acquisition of Cephalon.

May 11, 2011
Drugstore.com announces expiration of HSR waiting period for WAG deal

Drugstore.com on Tuesday announced the expiration of the waiting period under the U.S. Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to the proposed merger by which the company would be acquired by Walgreens in a cash transaction.

BELLEVUE, Wash. — Drugstore.com on Tuesday announced the expiration of the waiting period under the U.S. Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to the proposed merger by which the company would be acquired by Walgreens in a cash transaction.

The deal previously was announced on March 24.

April 28, 2011
Merck closer to acquiring Inspire

Merck has cleared a hurdle in its effort to buy eye care company Inspire Pharmaceuticals for $430 million, the company said Thursday.

WHITEHOUSE STATION, N.J. — Merck has cleared a hurdle in its effort to buy eye care company Inspire Pharmaceuticals for $430 million, the company said Thursday.

The expiration of the waiting period mandated by the Hart-Scott-Rodino Antitrust Improvements Act of 1976 brings Merck one step closer to acquiring Inspire.

Merck announced its intention to buy Raleigh, N.C.-based Inspire for $5 per share on April 15.

March 29, 2011
Catalyst, Walgreens move ahead with PBM acquisition

Catalyst Health Solutions and Walgreens on Monday announced that the Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

ROCKVILLE, Md. — Catalyst Health Solutions and Walgreens on Monday announced that the Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in connection with Catalyst’s previously announced proposed acquisition of Walgreens Health Initiatives, the pharmacy benefit management subsidiary of Walgreens.

Completion of the proposed acquisition remains subject to other closing conditions. The companies continue to expect to complete the transaction in the first half of 2011.

March 1, 2011
CVS Caremark closer to completing acquisition of Universal American's Part D business

In connection with the previously announced $1.25 billion acquisition of the Medicare Part D business of Universal American by CVS Caremark, both companies have announced that the Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Act.

WOONSOCKET, R.I., and RYE BROOK, N.Y. — In connection with the previously announced $1.25 billion acquisition of the Medicare Part D business of Universal American by CVS Caremark, both companies have announced that the Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Act.

The transaction is expected to close by the end of second quarter 2011 and is subject to customary closing conditions, including approval of Universal American shareholders and state regulatory approvals.

January 31, 2011
Pfizer: Tender offer for King completed

Pfizer has completed its tender offer for Bristol, Tenn.-based King Pharmaceuticals, Pfizer said Monday.

NEW YORK — Pfizer has completed its tender offer for Bristol, Tenn.-based King Pharmaceuticals, Pfizer said Monday.

Pfizer said 230.7 million shares valued at $14.25 each were tendered, representing about 92.5% of King.

Pfizer made its $3.6 billion offer for King in October 2010. The offer cleared the waiting period mandated by the Hart-Scott-Rodino Antitrust Improvements Act of 1976 on Friday.

December 16, 2010
Pfizer extends tender offer for King

A subsidiary of Pfizer has extended the expiration date of its tender offer to acquire all outstanding shares of common stock of King Pharmaceuticals.

NEW YORK — A subsidiary of Pfizer has extended the expiration date of its tender offer to acquire all outstanding shares of common stock of King Pharmaceuticals.

Parker Tennessee's tender offer now is scheduled to expire Jan. 21, as certain conditions to the tender offer wouldn't have been satisfied by the previously scheduled expiration date — which was Dec. 17 — including the expiration or earlier termination of any waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.

November 16, 2010
Energizer clears antitrust hurdle for American Safety Razor

Energizer Holdings has obtained U.S. antitrust clearance for the acquisition of American Safety Razor....

ST. LOUIS Energizer Holdings has obtained U.S. antitrust clearance for the acquisition of American Safety Razor.

The waiting period for the antitrust review under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 has expired. Clearance from regulatory authorities in Germany and Taiwan now must be satisfied before closing.

Energizer stated that it will continue to seek clearance from those authorities in advance of the Nov. 23 deadline in the Asset Purchase Agreement between Energizer and ASR.